Genesis Biotechnology Group, a consortium of an integrated group of biotechnology and research companies, announced that it has expanded its drug development services by the acquisition of PharmOptima.
PharmOptima, a preclinical Contract Research Organization company, joins Invivotek and Venenum Biodesign in the existing drug development segment of GBG. This acquisition expands GBG’s catalogue of available services, while providing the same high quality service each company’s clients have grown to expect. Effective with this acquisition, GBG will provide new and existing customers with the added value of a single point-of-contact for the efficient development and coordination of their unique preclinical drug development program.
According to Dr. Eli Mordechai, GBG’s CEO, “This partnership brings together highly complementary services of three companies creating a dynamic and efficient enterprise that will enable clients to have access to a comprehensive portfolio of bio-analytical and in vivo services in multiple therapeutic areas.” This spirit of collaboration was supported by PharmOptima’s CEO, Steven Weber, who stated, “PharmOptima is excited to become a part of the GBG consortium that will have the synergistic effect of expanding both the breadth and depth of expertise in advancing the drug development activities of our clients and partners.”
Date: June 24, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Cision